Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07623668 · ClinicalTrials.gov registry record · Phase 3
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
A Phase 3 study, sponsored by Oculis.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT07623668 is a Phase 3 study that is actively recruiting participants, run by Oculis. The registered enrollment target is 210 participants.
The verdict
NCT07623668, a Phase 3 study, is actively recruiting participants, sponsored by Oculis.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Interventions
- OTHER Placebo
- DRUG Methylprednisolone
- DRUG Privosegtor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07623668
The ClinicalTrials.gov registry entry for NCT07623668 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07623668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07623668 about?
NCT07623668 is a clinical study titled "Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research". The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolon...
What is the current status of trial NCT07623668?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2026-05-28. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07623668?
The interventions under investigation include: Placebo (OTHER), Methylprednisolone (DRUG), Privosegtor (DRUG).
Who is sponsoring clinical trial NCT07623668?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.